Identification

Name
Amiodarone
Accession Number
DB01118  (APRD00288)
Type
Small Molecule
Groups
Approved, Investigational
Description

An antianginal and antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting Na,K-activated myocardial adenosine triphosphatase. There is a resulting decrease in heart rate and in vascular resistance.

Structure
Thumb
Synonyms
  • 2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran
  • 2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone
  • 2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran
  • Amiodarona
  • Amiodaronum
Product Ingredients
IngredientUNIICASInChI Key
Amiodarone hydrochloride976728SY6Z19774-82-4ITPDYQOUSLNIHG-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AmiodaroneTablet200 mgOralSorres Pharma Inc2009-06-232014-06-20Canada
AmiodaroneTablet200 mgOralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
AmiodaroneTablet200 mgOralSanis Health Inc2011-06-10Not applicableCanada
Amiodarone for Injection 50mg/mlSolution50 mgIntravenousTeva2004-04-21Not applicableCanada
Amiodarone Hydrochloride for InjectionLiquid50 mgIntravenousSandoz Canada Incorporated2000-06-14Not applicableCanada
Amiodarone Hydrochloride for InjectionSolution50 mgIntravenousHospira, Inc.2002-08-29Not applicableCanada
Amiodarone Hydrochloride InjectionSolution50 mgIntravenousMylan PharmaceuticalsNot applicableNot applicableCanada
Amiodarone Hydrochloride InjectionSolution50 mgIntravenousFresenius Kabi2002-04-23Not applicableCanada
Amiodarone Hydrochloride InjectionSolution50 mgIntravenousMylan Pharmaceuticals2012-10-242016-07-06Canada
Amiodarone OmegaSolution50 mgIntravenousOmega Laboratories LtdNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amiodarone HClTablet200 mg/1OralMayne Pharma2013-01-01Not applicableUs
Amiodarone HClTablet100 mg/1OralCameron Pharmaceuticals2013-01-01Not applicableUs
Amiodarone HClTablet400 mg/1OralCameron Pharmaceuticals2013-01-01Not applicableUs
Amiodarone HClTablet100 mg/1OralMayne Pharma2017-01-01Not applicableUs
Amiodarone HClTablet400 mg/1OralMayne Pharma2013-01-01Not applicableUs
Amiodarone HClTablet200 mg/1OralCameron Pharmaceuticals2013-01-01Not applicableUs
Amiodarone hydrochlorideInjection, solution50 mg/mLIntravenousGland Pharma Limited2013-07-15Not applicableUs
Amiodarone HydrochlorideInjection, solution50 mg/mLIntravenousHospira, Inc.2002-10-182017-04-27Us
Amiodarone HydrochlorideInjection, solution50 mg/mLIntravenousHospira, Inc.2013-11-252017-11-01Us
Amiodarone HydrochlorideInjection, solution50 mg/mLIntravenousSagent Pharmaceuticals2013-07-15Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Amiodarone HClAmiodarone hydrochloride (1.8 mg/mL)Injection, solutionIntravenousCantrell Drug Company2011-08-01Not applicableUs
International/Other Brands
Amio-Aqueous IV / Aratac / Arycor / Atlansil / Tachyra
Categories
UNII
N3RQ532IUT
CAS number
1951-25-3
Weight
Average: 645.3116
Monoisotopic: 645.023680639
Chemical Formula
C25H29I2NO3
InChI Key
IYIKLHRQXLHMJQ-UHFFFAOYSA-N
InChI
InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3
IUPAC Name
{2-[4-(2-butyl-1-benzofuran-3-carbonyl)-2,6-diiodophenoxy]ethyl}diethylamine
SMILES
CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2

Pharmacology

Indication

Intravenously, for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Orally, for the treatment of life-threatening recurrent ventricular arrhythmias such as recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia.

Associated Conditions
Pharmacodynamics

Amiodarone belongs to a class of drugs called Vaughan-Williams Class III antiarrhythmic agents. It is used in the treatment of a wide range of cardiac tachyarhthmias, including both ventricular and supraventricular (atrial) arrhythmias. After intravenous administration in man, amiodarone relaxes vascular smooth muscle, reduces peripheral vascular resistance (afterload), and slightly increases cardiac index. Amiodarone prolongs phase 3 of the cardiac action potential. It has numerous other effects however, including actions that are similar to those of antiarrhythmic classes Ia, II, and IV. Amiodarone shows beta blocker-like and calcium channel blocker-like actions on the SA and AV nodes, increases the refractory period via sodium- and potassium-channel effects, and slows intra-cardiac conduction of the cardiac action potential, via sodium-channel effects.

Mechanism of action

The antiarrhythmic effect of amiodarone may be due to at least two major actions. It prolongs the myocardial cell-action potential (phase 3) duration and refractory period and acts as a noncompetitive a- and b-adrenergic inhibitor.

TargetActionsOrganism
APotassium voltage-gated channel subfamily H member 2
inhibitor
Human
ABeta-1 adrenergic receptor
antagonist
Human
UVoltage-dependent T-type calcium channel subunit alpha-1H
inhibitor
Human
AVoltage-dependent calcium channel subunit alpha-2/delta-2
inhibitor
Human
UThyroid hormone receptor alphaNot AvailableHuman
UThyroid hormone receptor betaNot AvailableHuman
UPeroxisome proliferator-activated receptor gammaNot AvailableHuman
Absorption

Slow and variable (about 20 to 55% of an oral dose is absorbed).

Volume of distribution
Not Available
Protein binding

>96%

Metabolism

Amiodarone is extensively metabolized in the liver via CYP2C8 (under 1% unchanged in urine), and can effect the metabolism of numerous other drugs. The major metabolite of amiodarone is desethylamiodarone (DEA), which also has antiarrhythmic properties. The metabolism of amiodarone is inhibited by grapefruit juice, leading to elevated serum levels of amiodarone.

Route of elimination

Amiodarone is eliminated primarily by hepatic metabolism and biliary excretion and there is negligible excretion of amiodarone or DEA in urine.

Half life

58 days (range 15-142 days)

Clearance
  • 90-158 mL/h/kg [Healthy with a single dose IV (5 mg/kg over 15 min)]
  • 100 mL/h/kg [Normal subjects > 65 yrs]
  • 150 mL/h/kg [younger subjects]
  • 220 and 440 mL/h/kg [patients with VT and VF]
Toxicity

Intravenous, mouse: LD50 = 178 mg/kg. Some side effects have a significant mortality rate: specifically, hepatitis, exacerbation of asthma and congestive failure, and pneumonitis.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Amiodarone Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Potassium voltage-gated channel subfamily H member 2MiRP1Not AvailableKCNE2ADR Directly StudiedThe presence of polymorphisms in KCNH2 and KCNE2 may potentially be associated with increased susceptibility to long Q-T syndrome or cardiac arrhytmia when treated with amiodarone.Details

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may decrease the antihypertensive activities of Amiodarone.Investigational
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Amiodarone.Experimental
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Amiodarone.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Amiodarone.Experimental, Illicit
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Amiodarone.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Amiodarone.Vet Approved
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Amiodarone.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Amiodarone.Experimental, Illicit
AbemaciclibThe risk or severity of adverse effects can be increased when Amiodarone is combined with Abemaciclib.Approved, Investigational
AbirateroneThe serum concentration of Amiodarone can be increased when it is combined with Abiraterone.Approved
AcebutololThe therapeutic efficacy of Acebutolol can be increased when used in combination with Amiodarone.Approved, Investigational
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Amiodarone.Approved, Investigational
AcemetacinAcemetacin may decrease the antihypertensive activities of Amiodarone.Approved, Experimental, Investigational
AcenocoumarolThe therapeutic efficacy of Acenocoumarol can be increased when used in combination with Amiodarone.Approved, Investigational
AcepromazineAmiodarone may increase the orthostatic hypotensive activities of Acepromazine.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Amiodarone.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Amiodarone.Approved
AcetohexamideAmiodarone may increase the hypoglycemic activities of Acetohexamide.Approved, Investigational, Withdrawn
Acetyl sulfisoxazoleThe metabolism of Acetyl sulfisoxazole can be decreased when combined with Amiodarone.Approved, Vet Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Amiodarone.Approved
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Amiodarone.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be increased when it is combined with Amiodarone.Experimental
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Amiodarone.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Amiodarone.Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Amiodarone.Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Amiodarone.Approved
Agalsidase betaThe therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Amiodarone.Approved, Investigational
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Amiodarone.Experimental, Investigational
AjmalineAmiodarone may increase the QTc-prolonging activities of Ajmaline.Approved, Investigational
AlaproclateThe serum concentration of Amiodarone can be increased when it is combined with Alaproclate.Experimental
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Amiodarone.Approved, Vet Approved
AlclofenacAlclofenac may decrease the antihypertensive activities of Amiodarone.Approved, Withdrawn
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Amiodarone.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Amiodarone is combined with Aldesleukin.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Amiodarone.Experimental, Investigational
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Amiodarone.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Amiodarone.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Amiodarone.Approved, Vet Approved
AliskirenThe metabolism of Aliskiren can be decreased when combined with Amiodarone.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Amiodarone.Approved
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Amiodarone.Experimental
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Amiodarone.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Amiodarone.Approved
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Amiodarone.Approved, Withdrawn
alpha-Tocopherol acetateThe metabolism of alpha-Tocopherol acetate can be decreased when combined with Amiodarone.Approved
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Amiodarone.Approved, Illicit, Investigational
AlprenololThe therapeutic efficacy of Alprenolol can be increased when used in combination with Amiodarone.Approved, Withdrawn
AmantadineAmantadine may increase the QTc-prolonging activities of Amiodarone.Approved
AmbenoniumAmbenonium may increase the bradycardic activities of Amiodarone.Approved
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Amiodarone.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Amiodarone.Approved, Investigational
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Amiodarone.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Amiodarone.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Amiloride.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Amiodarone.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Amiodarone.Approved
AmitrazAmitraz may increase the atrioventricular blocking (AV block) activities of Amiodarone.Vet Approved
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Amiodarone.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Amiodarone.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Amiodarone.Approved, Illicit
AmodiaquineThe metabolism of Amiodarone can be decreased when combined with Amodiaquine.Approved, Investigational
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Amiodarone.Approved, Investigational
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Amiodarone.Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Amiodarone.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amiodarone is combined with Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Amiodarone.Approved, Investigational
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Amiodarone.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amiodarone is combined with Amyl Nitrite.Approved
AnagrelideThe risk or severity of QTc prolongation can be increased when Anagrelide is combined with Amiodarone.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Amiodarone.Investigational
AndrostenedioneThe serum concentration of Androstenedione can be increased when it is combined with Amiodarone.Experimental, Illicit
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Amiodarone.Investigational
anecortave acetateThe serum concentration of anecortave acetate can be increased when it is combined with Amiodarone.Investigational
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Amiodarone.Approved, Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Amiodarone.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Amiodarone.Approved, Investigational
ApalutamideThe serum concentration of Apalutamide can be increased when it is combined with Amiodarone.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Amiodarone.Approved
ApocyninApocynin may decrease the antihypertensive activities of Amiodarone.Investigational
ApomorphineApomorphine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Apraclonidine.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Amiodarone.Approved, Investigational
AprepitantThe serum concentration of Amiodarone can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Amiodarone.Approved
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Amiodarone.Experimental
ArecolineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Arecoline.Experimental
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Amiodarone.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Amiodarone.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Amiodarone.Approved, Investigational
ArmodafinilThe metabolism of Amiodarone can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Amiodarone.Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Amiodarone is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Amiodarone is combined with Artemether.Approved
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Amiodarone resulting in a loss in efficacy.Approved, Investigational
AsenapineThe therapeutic efficacy of Asenapine can be increased when used in combination with Amiodarone.Approved
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Amiodarone.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Amiodarone.Approved, Investigational, Withdrawn
AtamestaneThe serum concentration of Atamestane can be increased when it is combined with Amiodarone.Investigational
AtazanavirThe serum concentration of Amiodarone can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe therapeutic efficacy of Atenolol can be increased when used in combination with Amiodarone.Approved
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Amiodarone.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Amiodarone is combined with Atorvastatin.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Amiodarone.Approved
AvatrombopagThe metabolism of Avatrombopag can be decreased when combined with Amiodarone.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Amiodarone.Approved, Investigational
AzapropazoneAzapropazone may decrease the antihypertensive activities of Amiodarone.Withdrawn
AzelastineThe metabolism of Azelastine can be decreased when combined with Amiodarone.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Azilsartan medoxomil.Approved, Investigational
AzithromycinAzithromycin may increase the QTc-prolonging activities of Amiodarone.Approved
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Amiodarone.Experimental
BalsalazideBalsalazide may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Amiodarone.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Amiodarone.Experimental
BarbitalBarbital may increase the hypotensive activities of Amiodarone.Illicit
BaricitinibThe metabolism of Baricitinib can be decreased when combined with Amiodarone.Approved, Investigational
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Amiodarone.Approved
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Amiodarone.Approved, Investigational
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Amiodarone.Approved
BefunololThe therapeutic efficacy of Befunolol can be increased when used in combination with Amiodarone.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Benazepril.Approved, Investigational
BendazacBendazac may decrease the antihypertensive activities of Amiodarone.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Bendroflumethiazide.Approved
BenidipineThe metabolism of Benidipine can be decreased when combined with Amiodarone.Approved, Investigational
BenorilateBenorilate may decrease the antihypertensive activities of Amiodarone.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Amiodarone.Withdrawn
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Amiodarone.Approved
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Amiodarone.Approved, Investigational
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Amiodarone.Approved, Illicit
BenzydamineBenzydamine may decrease the antihypertensive activities of Amiodarone.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Amiodarone.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Amiodarone.Approved, Withdrawn
BeractantAmiodarone may increase the bradycardic activities of Beractant.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Amiodarone.Approved, Vet Approved
BetaxololThe therapeutic efficacy of Betaxolol can be increased when used in combination with Amiodarone.Approved, Investigational
BethanecholThe risk or severity of adverse effects can be increased when Amiodarone is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Amiodarone.Approved
BevantololThe therapeutic efficacy of Bevantolol can be increased when used in combination with Amiodarone.Approved
BevoniumBevonium may decrease the antihypertensive activities of Amiodarone.Experimental
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Amiodarone.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Amiodarone.Approved, Investigational
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Amiodarone.Approved
BictegravirThe metabolism of Bictegravir can be decreased when combined with Amiodarone.Approved, Investigational
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Amiodarone.Approved, Investigational
BioallethrinThe metabolism of Bioallethrin can be decreased when combined with Amiodarone.Approved, Experimental
BisoprololThe therapeutic efficacy of Bisoprolol can be increased when used in combination with Amiodarone.Approved
BL-1020BL-1020 may increase the hypotensive activities of Amiodarone.Investigational
BlonanserinThe metabolism of Blonanserin can be decreased when combined with Amiodarone.Approved, Investigational
BoceprevirThe serum concentration of Amiodarone can be increased when it is combined with Boceprevir.Approved, Withdrawn
BopindololThe therapeutic efficacy of Bopindolol can be increased when used in combination with Amiodarone.Approved
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Amiodarone.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Amiodarone.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Amiodarone.Approved
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Amiodarone.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Amiodarone.Approved, Investigational
BretyliumBretylium may increase the bradycardic activities of Amiodarone.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Amiodarone.Approved, Investigational
BrigatinibThe metabolism of Brigatinib can be decreased when combined with Amiodarone.Approved, Investigational
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Amiodarone.Approved
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Amiodarone.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Amiodarone.Approved, Investigational
BromazepamThe metabolism of Bromazepam can be decreased when combined with Amiodarone.Approved, Illicit, Investigational
BromfenacBromfenac may decrease the antihypertensive activities of Amiodarone.Approved
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Amiodarone.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Amiodarone.Approved
BucillamineBucillamine may decrease the antihypertensive activities of Amiodarone.Investigational
BucindololThe therapeutic efficacy of Bucindolol can be increased when used in combination with Amiodarone.Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Amiodarone.Approved
BufexamacBufexamac may decrease the antihypertensive activities of Amiodarone.Approved, Experimental
BufuralolThe therapeutic efficacy of Bufuralol can be increased when used in combination with Amiodarone.Experimental, Investigational
BumadizoneBumadizone may decrease the antihypertensive activities of Amiodarone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Bumetanide.Approved
BunazosinAmiodarone may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Amiodarone.Approved, Investigational
BupranololThe therapeutic efficacy of Bupranolol can be increased when used in combination with Amiodarone.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Amiodarone.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Amiodarone.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
BuspironeThe metabolism of Buspirone can be decreased when combined with Amiodarone.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Amiodarone.Approved, Investigational
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Amiodarone.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Amiodarone.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Amiodarone.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Amiodarone.Approved
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Amiodarone.Approved, Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Amiodarone.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Amiodarone.Approved, Nutraceutical
Calcium AcetateThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Calcium Phosphate.Approved
CalfactantAmiodarone may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Amiodarone.Approved
CandesartanThe metabolism of Candesartan can be decreased when combined with Amiodarone.Experimental
Candesartan cilexetilThe metabolism of Candesartan cilexetil can be decreased when combined with Amiodarone.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Amiodarone.Withdrawn
CannabidiolThe metabolism of Cannabidiol can be decreased when combined with Amiodarone.Approved, Investigational
CapecitabineThe metabolism of Amiodarone can be decreased when combined with Capecitabine.Approved, Investigational
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Amiodarone.Experimental
CaptoprilThe metabolism of Captopril can be decreased when combined with Amiodarone.Approved
CarbacholThe risk or severity of adverse effects can be increased when Amiodarone is combined with Carbachol.Approved
CarbamazepineThe metabolism of Amiodarone can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Amiodarone.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Amiodarone is combined with Carbetocin.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Amiodarone.Approved
CarbutamideAmiodarone may increase the hypoglycemic activities of Carbutamide.Experimental
CariprazineThe metabolism of Cariprazine can be decreased when combined with Amiodarone.Approved, Investigational
CarprofenCarprofen may decrease the antihypertensive activities of Amiodarone.Approved, Vet Approved, Withdrawn
CarteololThe therapeutic efficacy of Carteolol can be increased when used in combination with Amiodarone.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Amiodarone.Approved, Investigational
CaseinThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Amiodarone.Approved
CastanospermineCastanospermine may decrease the antihypertensive activities of Amiodarone.Experimental
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Amiodarone.Approved, Investigational
CeliprololThe therapeutic efficacy of Celiprolol can be increased when used in combination with Amiodarone.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
CeritinibAmiodarone may increase the bradycardic activities of Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Amiodarone.Approved, Withdrawn
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Amiodarone.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Amiodarone.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Amiodarone.Approved
ChloramphenicolThe metabolism of Amiodarone can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Amiodarone.Approved, Illicit, Investigational
ChloroquineChloroquine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Chlorothiazide.Approved, Vet Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Amiodarone.Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Amiodarone.Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Amiodarone.Experimental
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Amiodarone.Approved, Investigational
ChlorthalidoneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Amiodarone.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Amiodarone.Approved, Nutraceutical
CholestyramineThe serum concentration of Amiodarone can be decreased when it is combined with Cholestyramine.Approved, Investigational
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Amiodarone.Approved
CibenzolineAmiodarone may increase the QTc-prolonging activities of Cibenzoline.Experimental
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Amiodarone.Approved, Investigational
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Amiodarone.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Cilnidipine.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Amiodarone.Approved, Investigational
CimetidineThe serum concentration of Amiodarone can be increased when it is combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Amiodarone.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Amiodarone.Approved, Investigational
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
CisaprideThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Amiodarone.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Amiodarone.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Amiodarone.Approved
ClemastineThe metabolism of Amiodarone can be decreased when combined with Clemastine.Approved, Investigational
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Amiodarone.Approved, Investigational
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Amiodarone.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Amiodarone.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Amiodarone.Approved, Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Amiodarone.Approved
ClobetasoneThe serum concentration of Clobetasone can be increased when it is combined with Amiodarone.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Amiodarone.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Clofarabine.Approved, Investigational
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Amiodarone.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Amiodarone.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Amiodarone.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Amiodarone.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Amiodarone.Approved
ClonixinClonixin may decrease the antihypertensive activities of Amiodarone.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Amiodarone.Approved
CloranololThe therapeutic efficacy of Cloranolol can be increased when used in combination with Amiodarone.Experimental
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Amiodarone.Approved, Illicit
ClorindioneThe therapeutic efficacy of Clorindione can be increased when used in combination with Amiodarone.Experimental
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Amiodarone.Approved, Illicit
ClotrimazoleThe metabolism of Amiodarone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Amiodarone.Approved
CobicistatThe serum concentration of Amiodarone can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Amiodarone.Approved, Investigational
CocaineThe metabolism of Cocaine can be decreased when combined with Amiodarone.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Amiodarone.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Amiodarone.Approved
ColesevelamThe serum concentration of Amiodarone can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Amiodarone can be decreased when it is combined with Colestipol.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Amiodarone.Approved, Investigational
Conjugated estrogensThe metabolism of Conjugated estrogens can be decreased when combined with Amiodarone.Approved
CopanlisibThe metabolism of Copanlisib can be decreased when combined with Amiodarone.Approved, Investigational
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Amiodarone.Investigational
Cortexolone 17α-propionateThe serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Amiodarone.Investigational
CorticosteroneThe serum concentration of Corticosterone can be increased when it is combined with Amiodarone.Experimental
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Amiodarone.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Amiodarone.Vet Approved
CrisaboroleThe metabolism of Amiodarone can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Amiodarone.Approved
CurcuminThe metabolism of Amiodarone can be decreased when combined with Curcumin.Approved, Investigational
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Amiodarone.Approved
CyclophosphamideThe risk or severity of pulmonary toxicity can be increased when Cyclophosphamide is combined with Amiodarone.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Amiodarone.Approved, Investigational, Vet Approved
CymarinThe serum concentration of Cymarin can be increased when it is combined with Amiodarone.Experimental
Cyproterone acetateThe serum concentration of Amiodarone can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe metabolism of Cytarabine can be decreased when combined with Amiodarone.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Amiodarone.Approved
DabrafenibThe serum concentration of Amiodarone can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirDaclatasvir may increase the bradycardic activities of Amiodarone.Approved, Investigational
DantroleneThe metabolism of Dantrolene can be decreased when combined with Amiodarone.Approved, Investigational
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Amiodarone.Approved
DapiprazoleAmiodarone may increase the orthostatic hypotensive activities of Dapiprazole.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Amiodarone.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Amiodarone.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Amiodarone.Approved, Investigational
DarunavirThe serum concentration of Amiodarone can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Amiodarone can be increased when it is combined with Dasabuvir.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Amiodarone.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Amiodarone.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Amiodarone.Approved, Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Amiodarone.Approved
DeferasiroxThe serum concentration of Amiodarone can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe metabolism of Deflazacort can be decreased when combined with Amiodarone.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Amiodarone.Approved
DelamanidAmiodarone may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Amiodarone.Approved
DemecariumDemecarium may increase the bradycardic activities of Amiodarone.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Amiodarone.Approved
DesipramineThe therapeutic efficacy of Desipramine can be increased when used in combination with Amiodarone.Approved, Investigational
DeslanosideThe serum concentration of Deslanoside can be increased when it is combined with Amiodarone.Approved
DesonideThe serum concentration of Desonide can be increased when it is combined with Amiodarone.Approved, Investigational
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Amiodarone.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Amiodarone.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Amiodarone.Experimental, Vet Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Amiodarone.Approved, Investigational
DetomidineDetomidine may increase the atrioventricular blocking (AV block) activities of Amiodarone.Vet Approved
DeutetrabenazineAmiodarone may increase the QTc-prolonging activities of Deutetrabenazine.Approved, Investigational
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Amiodarone.Vet Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Amiodarone.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Amiodarone.Approved, Illicit, Investigational, Withdrawn
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Amiodarone.Approved, Investigational
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Amiodarone.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Amiodarone.Approved, Investigational
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Amiodarone.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Amiodarone.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Amiodarone.Approved, Illicit, Investigational, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Amiodarone.Approved, Illicit, Investigational, Vet Approved
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Amiodarone.Vet Approved
DichlorvosDichlorvos may increase the bradycardic activities of Amiodarone.Vet Approved
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Amiodarone.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Diclofenamide.Approved, Investigational
DicoumarolThe therapeutic efficacy of Dicoumarol can be increased when used in combination with Amiodarone.Approved
DienogestThe serum concentration of Dienogest can be increased when it is combined with Amiodarone.Approved
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Amiodarone.Experimental
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Amiodarone.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Amiodarone.Approved, Investigational, Withdrawn
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Amiodarone.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Amiodarone.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Amiodarone.Approved
Digoxin Immune Fab (Ovine)The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Amiodarone.Approved
Dihydro-alpha-ergocryptineThe metabolism of Dihydro-alpha-ergocryptine can be decreased when combined with Amiodarone.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Amiodarone.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Amiodarone.Approved, Investigational
DiltiazemThe risk or severity of bradycardia can be increased when Diltiazem is combined with Amiodarone.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Amiodarone is combined with Dinutuximab.Approved, Investigational
DiphenadioneThe therapeutic efficacy of Diphenadione can be increased when used in combination with Amiodarone.Experimental
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Amiodarone.Approved, Investigational
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Amiodarone.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Amiodarone.Approved
DisopyramideAmiodarone may increase the QTc-prolonging activities of Disopyramide.Approved
DistigmineDistigmine may increase the bradycardic activities of Amiodarone.Experimental
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Amiodarone.Approved
DL-MethylephedrineDL-Methylephedrine may increase the atrioventricular blocking (AV block) activities of Amiodarone.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Amiodarone.Approved, Investigational
DoconexentThe metabolism of Doconexent can be decreased when combined with Amiodarone.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Amiodarone.Approved, Investigational
DolasetronDolasetron may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Amiodarone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Amiodarone.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Amiodarone.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Amiodarone.Approved
DosulepinThe metabolism of Amiodarone can be decreased when combined with Dosulepin.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Amiodarone.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Amiodarone.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Amiodarone.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Amiodarone.Approved, Investigational
DoxycyclineThe metabolism of Amiodarone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Amiodarone.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Amiodarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Amiodarone.Approved, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Amiodarone.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Amiodarone.Withdrawn
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Amiodarone.Approved, Investigational
DuloxetineAmiodarone may increase the orthostatic hypotensive activities of Duloxetine.Approved
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Amiodarone.Approved, Investigational
DuvelisibDuvelisib may decrease the antihypertensive activities of Amiodarone.Investigational
E-6201E-6201 may decrease the antihypertensive activities of Amiodarone.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Amiodarone.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Amiodarone.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Amiodarone.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Amiodarone.Approved
EfavirenzThe serum concentration of Amiodarone can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Amiodarone.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Efonidipine.Approved, Investigational
ElbasvirThe metabolism of Elbasvir can be decreased when combined with Amiodarone.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Amiodarone.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Amiodarone.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Amiodarone.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Amiodarone is combined with Empagliflozin.Approved
EnalaprilThe metabolism of Enalapril can be decreased when combined with Amiodarone.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Amiodarone is combined with Enalaprilat.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Amiodarone.Approved, Investigational
EncainideThe metabolism of Encainide can be decreased when combined with Amiodarone.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Amiodarone.Investigational
EnzalutamideThe serum concentration of Amiodarone can be decreased when it is combined with Enzalutamide.Approved
EpanololThe therapeutic efficacy of Epanolol can be increased when used in combination with Amiodarone.Experimental
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Amiodarone.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Epibatidine.Experimental
EpinastineThe metabolism of Epinastine can be decreased when combined with Amiodarone.Approved, Investigational
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Amiodarone.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Amiodarone.Approved
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Amiodarone.Approved
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Amiodarone.Approved
EprosartanThe risk or severity of adverse effects can be increased when Amiodarone is combined with Eprosartan.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Amiodarone.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Amiodarone.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Amiodarone.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Amiodarone.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Amiodarone.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Amiodarone.Approved
EribulinEribulin may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Amiodarone.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational, Vet Approved
EsatenololThe therapeutic efficacy of Esatenolol can be increased when used in combination with Amiodarone.Experimental
EscitalopramThe risk or severity of QTc prolongation can be increased when Amiodarone is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Amiodarone can be decreased when combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Amiodarone.Investigational
EsmololThe therapeutic efficacy of Esmolol can be increased when used in combination with Amiodarone.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Amiodarone.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Amiodarone.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
Estradiol acetateThe metabolism of Estradiol acetate can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
Estradiol benzoateThe metabolism of Estradiol benzoate can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
Estradiol cypionateThe metabolism of Estradiol cypionate can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
Estradiol dienanthateThe metabolism of Estradiol dienanthate can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
Estradiol valerateThe metabolism of Estradiol valerate can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Amiodarone.Approved, Investigational
Estrogens, esterifiedThe metabolism of Estrogens, esterified can be decreased when combined with Amiodarone.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Amiodarone.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Amiodarone.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Amiodarone.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Amiodarone is combined with Etacrynic acid.Approved, Investigational
EtanerceptEtanercept may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
EthanolThe metabolism of Ethanol can be decreased when combined with Amiodarone.Approved
EthenzamideEthenzamide may decrease the antihypertensive activities of Amiodarone.Experimental
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Amiodarone.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Amiodarone.Approved
Ethyl biscoumacetateThe therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Amiodarone.Withdrawn
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Amiodarone.Approved, Illicit
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Amiodarone.Approved
EtodolacThe metabolism of Etodolac can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Amiodarone.Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Amiodarone.Approved, Investigational
EtoperidoneThe serum concentration of Amiodarone can be increased when it is combined with Etoperidone.Withdrawn
EtoposideThe metabolism of Etoposide can be decreased when combined with Amiodarone.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Amiodarone.Approved, Investigational
EtravirineThe serum concentration of Amiodarone can be decreased when it is combined with Etravirine.Approved
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Amiodarone.Investigational, Nutraceutical
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Amiodarone.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Amiodarone.Approved, Investigational
ExisulindExisulind may decrease the antihypertensive activities of Amiodarone.Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Amiodarone.Approved, Investigational
FamotidineFamotidine may increase the QTc-prolonging activities of Amiodarone.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Amiodarone.Approved
FelbinacFelbinac may decrease the antihypertensive activities of Amiodarone.Experimental
FelodipineThe metabolism of Felodipine can be decreased when combined with Amiodarone.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Amiodarone.Approved
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Amiodarone.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Amiodarone is combined with Fenoldopam.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Amiodarone.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Amiodarone.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Amiodarone.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Amiodarone.Experimental
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Amiodarone.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Amiodarone.Experimental
Ferulic acidFerulic acid may decrease the antihypertensive activities of Amiodarone.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amiodarone.Approved
FimasartanThe risk or severity of adverse effects can be increased when Amiodarone is combined with Fimasartan.Approved, Investigational
FinasterideThe metabolism of Finasteride can be decreased when combined with Amiodarone.Approved
FingolimodFingolimod may increase the arrhythmogenic activities of Amiodarone.Approved, Investigational
FlecainideThe serum concentration of Flecainide can be increased when it is combined with Amiodarone.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Amiodarone.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Floctafenine.Approved, Withdrawn
FloxuridineThe metabolism of Amiodarone can be decreased when combined with Floxuridine.Approved
FluasteroneThe serum concentration of Fluasterone can be increased when it is combined with Amiodarone.Investigational
FluconazoleThe metabolism of Amiodarone can be decreased when combined with Fluconazole.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Amiodarone.Approved, Investigational
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Amiodarone.Approved, Investigational
FluindioneThe therapeutic efficacy of Fluindione can be increased when used in combination with Amiodarone.Approved, Investigational
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Amiodarone.Approved, Vet Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Amiodarone.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Amiodarone.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Amiodarone.Approved, Illicit
FlunixinFlunixin may decrease the antihypertensive activities of Amiodarone.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Amiodarone.Experimental
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Amiodarone.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Amiodarone.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Amiodarone.Approved, Withdrawn
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Amiodarone.Approved, Investigational
FluorouracilThe metabolism of Amiodarone can be decreased when combined with Fluorouracil.Approved
FluoxetineThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Amiodarone.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Amiodarone.Approved, Investigational, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Amiodarone.Approved
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Amiodarone.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Amiodarone.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Amiodarone.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Amiodarone.Approved, Illicit, Investigational
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Amiodarone.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Amiodarone.Approved, Investigational
FluticasoneThe serum concentration of Fluticasone can be increased when it is combined with Amiodarone.Approved, Experimental, Investigational
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Amiodarone.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Amiodarone.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Amiodarone.Experimental
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Amiodarone.Approved
FluvoxamineThe metabolism of Amiodarone can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Amiodarone.Approved, Investigational, Withdrawn
FormoterolThe metabolism of Formoterol can be decreased when combined with Amiodarone.Approved, Investigational
FosamprenavirThe serum concentration of Amiodarone can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Amiodarone can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Amiodarone.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Fosinopril.Approved
FosnetupitantThe metabolism of Fosnetupitant can be decreased when combined with Amiodarone.Approved
FosphenytoinThe serum concentration of Amiodarone can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FostamatinibThe metabolism of Fostamatinib can be decreased when combined with Amiodarone.Approved, Investigational
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Amiodarone.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Amiodarone can be increased when it is combined with Fusidic Acid.Approved, Investigational
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Amiodarone.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Amiodarone.Approved
GavestinelThe metabolism of Gavestinel can be decreased when combined with Amiodarone.Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Amiodarone.Approved, Investigational
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Amiodarone.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Amiodarone.Approved, Investigational, Nutraceutical
GitoformateThe serum concentration of Gitoformate can be increased when it is combined with Amiodarone.Experimental
GlibornurideAmiodarone may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideThe metabolism of Gliclazide can be decreased when combined with Amiodarone.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Amiodarone.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Amiodarone.Approved, Investigational
GliquidoneAmiodarone may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideAmiodarone may increase the hypoglycemic activities of Glisoxepide.Investigational
GlyburideThe metabolism of Glyburide can be decreased when combined with Amiodarone.Approved
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Amiodarone.Experimental
GoserelinGoserelin may increase the QTc-prolonging activities of Amiodarone.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
GrazoprevirThe metabolism of Grazoprevir can be decreased when combined with Amiodarone.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Amiodarone.Approved, Investigational, Withdrawn
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Amiodarone.Approved, Investigational, Vet Approved
GTS-21The risk or severity of adverse effects can be increased when Amiodarone is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Amiodarone.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Amiodarone.Approved, Investigational
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Amiodarone.Approved, Investigational
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Amiodarone.Experimental
HalcinonideThe serum concentration of Halcinonide can be increased when it is combined with Amiodarone.Approved, Investigational, Withdrawn
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Amiodarone.Approved
HaloperidolHaloperidol may increase the QTc-prolonging activities of Amiodarone.Approved
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Amiodarone.Approved, Withdrawn
HalothaneThe metabolism of Halothane can be decreased when combined with Amiodarone.Approved, Vet Approved
HE3286The serum concentration of HE3286 can be increased when it is combined with Amiodarone.Investigational
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Amiodarone.Approved, Investigational
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Amiodarone.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Amiodarone.Investigational
HistamineThe metabolism of Histamine can be decreased when combined with Amiodarone.Approved, Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Amiodarone.Approved
Huperzine AHuperzine A may increase the bradycardic activities of Amiodarone.Approved, Investigational
HydralazineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Amiodarone resulting in a loss in efficacy.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Amiodarone.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Hydroflumethiazide.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Amiodarone.Approved, Illicit
HydroxychloroquineThe metabolism of Amiodarone can be decreased when combined with Hydroxychloroquine.Approved
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Amiodarone.Approved, Investigational
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Amiodarone.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Amiodarone.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Amiodarone.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Amiodarone.Withdrawn
IbutilideThe risk or severity of QTc prolongation can be increased when Ibutilide is combined with Amiodarone.Approved
IcatibantIcatibant may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
IcotinibThe metabolism of Icotinib can be decreased when combined with Amiodarone.Approved, Investigational
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Amiodarone.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Amiodarone.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Amiodarone resulting in a loss in efficacy.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Amiodarone.Approved
IloprostThe risk or severity of adverse effects can be increased when Amiodarone is combined with Iloprost.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Amiodarone.Approved
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Amiodarone.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Imidapril.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Amiodarone.Experimental
ImipramineThe metabolism of Imipramine can be decreased when combined with Amiodarone.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Amiodarone.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Amiodarone.Approved
IndalpineThe serum concentration of Amiodarone can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe metabolism of Indapamide can be decreased when combined with Amiodarone.Approved
IndenololThe therapeutic efficacy of Indenolol can be increased when used in combination with Amiodarone.Withdrawn
IndinavirThe serum concentration of Amiodarone can be increased when it is combined with Indinavir.Approved
IndisulamThe metabolism of Indisulam can be decreased when combined with Amiodarone.Investigational
IndobufenIndobufen may decrease the antihypertensive activities of Amiodarone.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Amiodarone.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Amiodarone.Withdrawn
IndoraminAmiodarone may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin HumanAmiodarone may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin PorkAmiodarone may increase the hypoglycemic activities of Insulin Pork.Approved
Iodide I-131The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Amiodarone.Approved, Investigational
IpecacThe metabolism of Ipecac can be decreased when combined with Amiodarone.Approved, Withdrawn
IpidacrineIpidacrine may increase the bradycardic activities of Amiodarone.Experimental
IpratropiumThe metabolism of Ipratropium bromide can be decreased when combined with Amiodarone.Approved
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Amiodarone.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Amiodarone.Approved, Investigational
IsavuconazoleThe serum concentration of Isavuconazole can be increased when it is combined with Amiodarone.Approved, Investigational
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Amiodarone.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Amiodarone is combined with Isocarboxazid.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Amiodarone.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Amiodarone.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Amiodarone.Approved, Investigational, Withdrawn
IsoniazidThe metabolism of Amiodarone can be decreased when combined with Isoniazid.Approved, Investigational
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Amiodarone.Approved, Investigational
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Amiodarone.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Amiodarone.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Isradipine can be decreased when combined with Amiodarone.Approved, Investigational
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Amiodarone.Investigational
ItraconazoleThe metabolism of Amiodarone can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Amiodarone.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Amiodarone.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Amiodarone.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Amiodarone.Approved, Investigational
KebuzoneKebuzone may decrease the antihypertensive activities of Amiodarone.Experimental
KetamineThe metabolism of Ketamine can be decreased when combined with Amiodarone.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Amiodarone.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Amiodarone.Approved, Investigational
KetoconazoleThe metabolism of Amiodarone can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Amiodarone.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Amiodarone.Approved
LabetalolThe therapeutic efficacy of Labetalol can be increased when used in combination with Amiodarone.Approved
LacidipineThe serum concentration of Lacidipine can be increased when it is combined with Amiodarone.Approved, Investigational
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Amiodarone.Approved
Lanatoside CThe serum concentration of Lanatoside C can be increased when it is combined with Amiodarone.Experimental
LandiololThe therapeutic efficacy of Landiolol can be increased when used in combination with Amiodarone.Investigational
LanreotideAmiodarone may increase the bradycardic activities of Lanreotide.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Amiodarone.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Amiodarone.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Amiodarone.Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Amiodarone.Approved
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Amiodarone.Approved
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Amiodarone.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Amiodarone.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Amiodarone.Approved, Investigational
LetermovirThe metabolism of Letermovir can be decreased when combined with Amiodarone.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Amiodarone.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
LevobetaxololThe therapeutic efficacy of Levobetaxolol can be increased when used in combination with Amiodarone.Approved, Investigational
LevobunololThe therapeutic efficacy of Levobunolol can be increased when used in combination with Amiodarone.Approved
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Amiodarone.Approved, Investigational
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Amiodarone.Approved
LevodopaAmiodarone may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Amiodarone.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Amiodarone.Approved, Investigational
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Amiodarone.Approved
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Amiodarone.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Amiodarone is combined with Levosimendan.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Amiodarone.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Amiodarone.Investigational
LidocaineThe risk or severity of generalized seizure and bradycardia can be increased when Amiodarone is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Amiodarone.Approved
LisdexamfetamineAmiodarone may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Amiodarone.Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Amiodarone.Approved, Investigational
LithiumLithium may increase the QTc-prolonging activities of Amiodarone.Approved
LobeglitazoneThe metabolism of Amiodarone can be decreased when combined with Lobeglitazone.Approved, Investigational
LobelineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Lobeline.Investigational
LofexidineThe metabolism of Lofexidine can be decreased when combined with Amiodarone.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Amiodarone.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Amiodarone.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Amiodarone.Experimental
LoperamideThe metabolism of Loperamide can be decreased when combined with Amiodarone.Approved
LopinavirThe serum concentration of Amiodarone can be increased when it is combined with Lopinavir.Approved
LorajmineAmiodarone may increase the QTc-prolonging activities of Lorajmine.Experimental
LoratadineThe risk or severity of QTc prolongation and torsade de pointes can be increased when Amiodarone is combined with Loratadine.Approved, Investigational
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Amiodarone.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Amiodarone.Approved, Investigational
LorpiprazoleThe serum concentration of Amiodarone can be increased when it is combined with Lorpiprazole.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Amiodarone.Approved
LoteprednolThe serum concentration of Loteprednol can be increased when it is combined with Amiodarone.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Amiodarone.Approved, Investigational
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
LucinactantAmiodarone may increase the bradycardic activities of Lucinactant.Approved, Investigational
LuliconazoleThe serum concentration of Amiodarone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Amiodarone can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Amiodarone.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Amiodarone.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Amiodarone.Approved, Investigational
MacimorelinAmiodarone may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Amiodarone.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Amiodarone is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Amiodarone is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Amiodarone is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Amiodarone is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
MalathionMalathion may increase the bradycardic activities of Amiodarone.Approved, Investigational
ManidipineThe metabolism of Amiodarone can be decreased when combined with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Amiodarone is combined with Mannitol.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Amiodarone.Approved, Investigational
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Amiodarone.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
ME-609The serum concentration of ME-609 can be increased when it is combined with Amiodarone.Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Amiodarone.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Mecamylamine.Approved, Investigational
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Amiodarone.Approved, Vet Approved
MedetomidineMedetomidine may increase the atrioventricular blocking (AV block) activities of Amiodarone.Vet Approved
Medical CannabisThe metabolism of Medical Cannabis can be decreased when combined with Amiodarone.Experimental, Investigational
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Amiodarone.Approved, Investigational
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Amiodarone.Approved
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Amiodarone.Approved
MefloquineThe metabolism of Mefloquine can be decreased when combined with Amiodarone.Approved, Investigational
MelatoninThe metabolism of Melatonin can be decreased when combined with Amiodarone.Approved, Nutraceutical, Vet Approved
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Amiodarone.Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Amiodarone.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Amiodarone.Approved, Investigational
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Amiodarone.Experimental
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Amiodarone.Investigational, Withdrawn
MepindololThe therapeutic efficacy of Mepindolol can be increased when used in combination with Amiodarone.Experimental
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Amiodarone.Approved, Vet Approved
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Amiodarone.Approved
MesalazineMesalazine may decrease the antihypertensive activities of Amiodarone.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Amiodarone.Approved, Investigational
MestranolThe metabolism of Mestranol can be decreased when combined with Amiodarone.Approved
MetahexamideAmiodarone may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Amiodarone.Approved, Investigational, Withdrawn
MethacholineAmiodarone may increase the bronchoconstrictory activities of Methacholine.Approved, Investigational
MethadoneMethadone may increase the QTc-prolonging activities of Amiodarone.Approved
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Amiodarone.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Amiodarone.Investigational
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Amiodarone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Amiodarone.Approved
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Amiodarone.Approved, Investigational
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Amiodarone.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Methyclothiazide.Approved
MethyldopaMethyldopa may increase the atrioventricular blocking (AV block) activities of Amiodarone.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Amiodarone.Approved, Investigational
MethylergometrineAmiodarone may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Amiodarone.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Amiodarone.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Amiodarone.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Amiodarone.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Amiodarone.Approved, Illicit, Withdrawn
MetildigoxinThe serum concentration of Metildigoxin can be increased when it is combined with Amiodarone.Experimental
MetipranololThe therapeutic efficacy of Metipranolol can be increased when used in combination with Amiodarone.Approved
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Amiodarone.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Amiodarone.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Amiodarone.Approved
MevastatinThe serum concentration of Mevastatin can be decreased when it is combined with Amiodarone.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Amiodarone.Approved, Investigational
MianserinThe metabolism of Mianserin can be decreased when combined with Amiodarone.Approved, Investigational
MibefradilThe metabolism of Mibefradil can be decreased when combined with Amiodarone.Investigational, Withdrawn
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Amiodarone.Approved, Investigational
MiconazoleThe metabolism of Miconazole can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Amiodarone.Approved, Illicit
MidecamycinThe metabolism of Midecamycin can be decreased when combined with Amiodarone.Approved
MidodrineAmiodarone may increase the bradycardic activities of Midodrine.Approved
MidostaurinThe metabolism of Midostaurin can be decreased when combined with Amiodarone.Approved, Investigational
MifepristoneAmiodarone may increase the QTc-prolonging activities of Mifepristone.Approved, Investigational
MilnacipranThe serum concentration of Amiodarone can be increased when it is combined with Milnacipran.Approved, Investigational
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Amiodarone.Approved, Investigational
MinaprineThe metabolism of Minaprine can be decreased when combined with Amiodarone.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Minoxidil.Approved, Investigational
MipomersenAmiodarone may increase the hepatotoxic activities of Mipomersen.Approved, Investigational
MirabegronThe metabolism of Mirabegron can be decreased when combined with Amiodarone.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Amiodarone.Approved
MitotaneThe serum concentration of Amiodarone can be decreased when it is combined with Mitotane.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Amiodarone.Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Amiodarone.Approved, Investigational
ModafinilThe metabolism of Modafinil can be decreased when combined with Amiodarone.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Amiodarone.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Amiodarone.Experimental
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Amiodarone.Approved, Vet Approved
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Amiodarone.Vet Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Amiodarone.Approved
MoricizineMoricizine may increase the hypotensive activities of Amiodarone.Approved, Investigational, Withdrawn
MorphineThe metabolism of Morphine can be decreased when combined with Amiodarone.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Amiodarone.Approved, Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Amiodarone.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Amiodarone.Approved
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Amiodarone.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Nabilone.Approved, Investigational
NabiximolsThe metabolism of Nabiximols can be decreased when combined with Amiodarone.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Amiodarone.Approved
NadololThe therapeutic efficacy of Nadolol can be increased when used in combination with Amiodarone.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
NafcillinThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Amiodarone.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Amiodarone.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Amiodarone.Approved, Vet Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Amiodarone.Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Amiodarone.Approved, Vet Approved
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Amiodarone.Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Amiodarone.Approved, Investigational
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Amiodarone.Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Amiodarone.Approved, Investigational
NefazodoneThe metabolism of Amiodarone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Amiodarone can be increased when it is combined with Nelfinavir.Approved
NeostigmineNeostigmine may increase the bradycardic activities of Amiodarone.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
NeratinibThe metabolism of Neratinib can be decreased when combined with Amiodarone.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Amiodarone can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Amiodarone can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Nicardipine can be decreased when combined with Amiodarone.Approved, Investigational
NicergolineThe metabolism of Nicergoline can be decreased when combined with Amiodarone.Approved, Investigational
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
NicorandilNicorandil may increase the hypotensive activities of Amiodarone.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Amiodarone.Approved
NifedipineThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Amiodarone.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Amiodarone.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Amiodarone.Approved
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Amiodarone.Experimental
NiguldipineAmiodarone may increase the orthostatic hypotensive activities of Niguldipine.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Amiodarone.Investigational
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Amiodarone.Approved, Investigational
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Amiodarone.Approved, Investigational
NimesulideNimesulide may decrease the antihypertensive activities of Amiodarone.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Amiodarone.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Amiodarone.Approved
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Amiodarone.Approved
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Amiodarone.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Amiodarone.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Amiodarone.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Amiodarone.Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Amiodarone is combined with Nitroglycerin.Approved, Investigational
NitroprussideAmiodarone may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Amiodarone is combined with Nitrous acid.Approved, Investigational
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Amiodarone.Approved
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Amiodarone.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Amiodarone.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Amiodarone.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Amiodarone.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Amiodarone.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Amiodarone.Approved, Vet Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Amiodarone is combined with Obinutuzumab.Approved, Investigational
OctreotideOctreotide may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Amiodarone.Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Amiodarone.Approved
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Amiodarone.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Amiodarone.Approved
OleandrinThe serum concentration of Oleandrin can be increased when it is combined with Amiodarone.Experimental, Investigational
Oleoyl-estroneThe serum concentration of Oleoyl-estrone can be increased when it is combined with Amiodarone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Amiodarone is combined with Olmesartan.Approved, Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Amiodarone.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Amiodarone.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Amiodarone.Approved
OmbitasvirThe serum concentration of Amiodarone can be increased when it is combined with Ombitasvir.Approved, Investigational
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Amiodarone.Experimental
OndansetronOndansetron may increase the QTc-prolonging activities of Amiodarone.Approved
OpiumThe metabolism of Opium can be decreased when combined with Amiodarone.Approved, Illicit
OrgoteinOrgotein may decrease the antihypertensive activities of Amiodarone.Vet Approved
OrlistatOrlistat can cause a decrease in the absorption of Amiodarone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Amiodarone.Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Amiodarone.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Amiodarone.Approved, Investigational
OuabainThe serum concentration of Ouabain can be increased when it is combined with Amiodarone.Approved
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Amiodarone.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Amiodarone.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Amiodarone.Approved
OxprenololThe therapeutic efficacy of Oxprenolol can be increased when used in combination with Amiodarone.Approved
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Amiodarone.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Oxycodone.Approved, Illicit, Investigational
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Amiodarone.Approved, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Amiodarone.Approved, Withdrawn
OxytocinOxytocin may increase the QTc-prolonging activities of Amiodarone.Approved, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Amiodarone.Approved, Vet Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Amiodarone.Investigational
PalbociclibThe serum concentration of Palbociclib can be increased when it is combined with Amiodarone.Approved, Investigational
PaliperidoneThe risk or severity of QTc prolongation can be increased when Amiodarone is combined with Paliperidone.Approved
PalmidrolPalmidrol may decrease the antihypertensive activities of Amiodarone.Experimental, Nutraceutical
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Amiodarone.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Amiodarone.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Amiodarone.Approved
PapaverineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Papaverine.Approved, Investigational
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Amiodarone.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Amiodarone.Approved
ParaoxonParaoxon may increase the bradycardic activities of Amiodarone.Experimental
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Amiodarone.Approved
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Amiodarone.Approved, Investigational
ParitaprevirThe serum concentration of Amiodarone can be increased when it is combined with Paritaprevir.Approved, Investigational
ParoxetineThe metabolism of Amiodarone can be decreased when combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Amiodarone.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Amiodarone.Approved
Peginterferon alfa-2bThe serum concentration of Amiodarone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe therapeutic efficacy of Penbutolol can be increased when used in combination with Amiodarone.Approved, Investigational
PentamidinePentamidine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
PentobarbitalThe metabolism of Amiodarone can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Amiodarone.Approved
PerazinePerazine may increase the hypotensive activities of Amiodarone.Approved, Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Amiodarone.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Amiodarone.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Perindopril.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Amiodarone.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Amiodarone.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Amiodarone.Approved
PeruvosideThe serum concentration of Peruvoside can be increased when it is combined with Amiodarone.Experimental
PethidineThe metabolism of Pethidine can be decreased when combined with Amiodarone.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Amiodarone.Withdrawn
PhenelzineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Phenelzine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Amiodarone.Approved, Investigational, Withdrawn
PhenindioneThe therapeutic efficacy of Phenindione can be increased when used in combination with Amiodarone.Approved, Investigational
PhenobarbitalThe metabolism of Amiodarone can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Amiodarone.Approved
PhenprocoumonThe therapeutic efficacy of Phenprocoumon can be increased when used in combination with Amiodarone.Approved, Investigational
PhentolamineAmiodarone may increase the orthostatic hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Amiodarone.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Amiodarone.Approved, Vet Approved
PhysostigminePhysostigmine may increase the bradycardic activities of Amiodarone.Approved, Investigational
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Amiodarone.Approved, Investigational
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Amiodarone.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Amiodarone.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Amiodarone.Approved
PindololThe therapeutic efficacy of Pindolol can be increased when used in combination with Amiodarone.Approved, Investigational
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Amiodarone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Pipamperone.Approved, Investigational
PiperaquineThe metabolism of Piperaquine can be decreased when combined with Amiodarone.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Amiodarone.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Amiodarone.Approved, Investigational
PirfenidonePirfenidone may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Amiodarone.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Amiodarone.Experimental
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Amiodarone.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Amiodarone.Approved, Investigational
PizotifenAmiodarone may increase the orthostatic hypotensive activities of Pizotifen.Approved
Platelet Activating FactorThe therapeutic efficacy of Platelet Activating Factor can be increased when used in combination with Amiodarone.Experimental
PodofiloxThe metabolism of Podofilox can be decreased when combined with Amiodarone.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Amiodarone.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Amiodarone.Approved, Investigational
Poractant alfaAmiodarone may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe metabolism of Amiodarone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololThe therapeutic efficacy of Practolol can be increased when used in combination with Amiodarone.Approved
PrajmalineAmiodarone may increase the QTc-prolonging activities of Prajmaline.Experimental
PramipexoleThe risk or severity of adverse effects can be increased when Amiodarone is combined with Pramipexole.Approved, Investigational
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Amiodarone.Approved, Investigational
PranoprofenPranoprofen may decrease the antihypertensive activities of Amiodarone.Experimental, Investigational
PrasteroneThe metabolism of Prasterone can be decreased when combined with Amiodarone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe serum concentration of Prasterone sulfate can be increased when it is combined with Amiodarone.Investigational
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Amiodarone resulting in a loss in efficacy.Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Amiodarone.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Amiodarone.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
PrazosinAmiodarone may increase the orthostatic hypotensive activities of Prazosin.Approved
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Amiodarone.Approved, Investigational
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Amiodarone.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Amiodarone.Approved, Vet Approved
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Amiodarone.Approved, Experimental, Investigational
PrimaquinePrimaquine may increase the QTc-prolonging activities of Amiodarone.Approved
PrimidoneThe metabolism of Amiodarone can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideAmiodarone may increase the QTc-prolonging activities of Procainamide.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Amiodarone.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Amiodarone.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Amiodarone.Experimental
ProguanilThe metabolism of Proguanil can be decreased when combined with Amiodarone.Approved
PromazinePromazine may increase the QTc-prolonging activities of Amiodarone.Approved, Vet Approved
PromethazineThe metabolism of Promethazine can be decreased when combined with Amiodarone.Approved, Investigational
PropacetamolPropacetamol may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
PropafenoneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Propafenone.Approved
PropericiazineAmiodarone may increase the orthostatic hypotensive activities of Propericiazine.Approved, Investigational
PropiomazineAmiodarone may increase the orthostatic hypotensive activities of Propiomazine.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Amiodarone.Vet Approved
PropiverineThe metabolism of Propiverine can be decreased when combined with Amiodarone.Approved, Investigational
PropofolThe metabolism of Propofol can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
PropranololThe therapeutic efficacy of Propranolol can be increased when used in combination with Amiodarone.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Amiodarone.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Amiodarone.Experimental
ProscillaridinThe serum concentration of Proscillaridin can be increased when it is combined with Amiodarone.Experimental
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Amiodarone.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Amiodarone.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Amiodarone.Approved
PTC299PTC299 may decrease the antihypertensive activities of Amiodarone.Investigational
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Amiodarone.Approved, Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Amiodarone.Approved, Investigational
PyrimethamineThe metabolism of Amiodarone can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Amiodarone.Experimental
QuazepamThe metabolism of Quazepam can be decreased when combined with Amiodarone.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Amiodarone.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Amiodarone.Approved, Investigational
QuinaprilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Quinapril.Approved, Investigational
QuinidineAmiodarone may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Quinine is combined with Amiodarone.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Amiodarone.Approved, Investigational
RacepinephrineRacepinephrine may increase the atrioventricular blocking (AV block) activities of Amiodarone.Approved
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Amiodarone.Experimental
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Amiodarone.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Amiodarone.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Ramipril.Approved
RanitidineThe metabolism of Ranitidine can be decreased when combined with Amiodarone.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Amiodarone.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Rasagiline.Approved
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Amiodarone.Approved, Investigational
RegorafenibRegorafenib may increase the bradycardic activities of Amiodarone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Remifentanil.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Amiodarone.Approved, Withdrawn
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Amiodarone.Approved, Investigational
RepinotanThe metabolism of Repinotan can be decreased when combined with Amiodarone.Investigational
ReserpineReserpine may increase the hypotensive activities of Amiodarone.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Amiodarone.Approved, Experimental, Investigational
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Amiodarone.Approved
RibociclibThe risk or severity of QTc prolongation can be increased when Ribociclib is combined with Amiodarone.Approved, Investigational
RifabutinThe metabolism of Amiodarone can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Amiodarone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Amiodarone can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Amiodarone.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Amiodarone.Approved
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Amiodarone.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Amiodarone.Approved, Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Amiodarone.Approved
RisperidoneAmiodarone may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe serum concentration of Amiodarone can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Amiodarone.Approved
RivastigmineAmiodarone may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Amiodarone.Approved, Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Amiodarone.Approved, Investigational
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Amiodarone.Approved, Investigational
RomifidineRomifidine may increase the atrioventricular blocking (AV block) activities of Amiodarone.Vet Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Amiodarone.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Amiodarone.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Amiodarone.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Amiodarone.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Amiodarone.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Amiodarone.Approved, Investigational, Withdrawn
RucaparibThe metabolism of Rucaparib can be decreased when combined with Amiodarone.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Amiodarone.Approved
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Amiodarone.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Sacubitril.Approved
SafinamideThe metabolism of Safinamide can be decreased when combined with Amiodarone.Approved, Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Amiodarone.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Amiodarone.Approved
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Amiodarone.Experimental
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Amiodarone.Approved
SalmeterolThe metabolism of Salmeterol can be decreased when combined with Amiodarone.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Amiodarone.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
SaquinavirThe serum concentration of Amiodarone can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Amiodarone.Approved
SecobarbitalThe metabolism of Amiodarone can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Amiodarone.Approved
SemapimodSemapimod may decrease the antihypertensive activities of Amiodarone.Investigational
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Amiodarone.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Amiodarone.Investigational
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Amiodarone.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Amiodarone.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Amiodarone.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Amiodarone.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Amiodarone.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Amiodarone.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Amiodarone.Approved
SiltuximabThe serum concentration of Amiodarone can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Amiodarone.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Amiodarone.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Amiodarone.Experimental
SirolimusThe metabolism of Sirolimus can be decreased when combined with Amiodarone.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Amiodarone.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Amiodarone.Approved, Investigational, Withdrawn
SofosbuvirSofosbuvir may increase the bradycardic activities of Amiodarone.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Amiodarone.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Amiodarone.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Amiodarone.Approved, Investigational
SotalolThe therapeutic efficacy of Sotalol can be increased when used in combination with Amiodarone.Approved
SparteineAmiodarone may increase the QTc-prolonging activities of Sparteine.Experimental
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Amiodarone.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Spironolactone.Approved
SRT501SRT501 may decrease the antihypertensive activities of Amiodarone.Investigational
St. John's WortThe serum concentration of Amiodarone can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Amiodarone can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Amiodarone is combined with Streptokinase.Approved, Investigational
SufentanilThe metabolism of Sufentanil can be decreased when combined with Amiodarone.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Amiodarone.Approved
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Amiodarone.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Amiodarone.Approved
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Amiodarone.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Amiodarone.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Amiodarone.Approved, Vet Approved
SulindacSulindac may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
SunitinibThe metabolism of Sunitinib can be decreased when combined with Amiodarone.Approved, Investigational
SuprofenThe metabolism of Suprofen can be decreased when combined with Amiodarone.Approved, Withdrawn
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Amiodarone.Approved, Investigational
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Amiodarone.Experimental
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Amiodarone.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Amiodarone.Approved
TacrineTacrine may increase the bradycardic activities of Amiodarone.Investigational, Withdrawn
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Amiodarone.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Amiodarone.Approved, Investigational
TafenoquineThe metabolism of Amiodarone can be decreased when combined with Tafenoquine.Investigational
TalinololThe therapeutic efficacy of Talinolol can be increased when used in combination with Amiodarone.Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Amiodarone.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Amiodarone.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Amiodarone.Approved
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Amiodarone.Investigational
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Amiodarone.Approved, Investigational
TasosartanThe metabolism of Tasosartan can be decreased when combined with Amiodarone.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Amiodarone.Experimental
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Amiodarone.Approved, Investigational
TegafurThe serum concentration of the active metabolites of Tegafur can be reduced when Tegafur is used in combination with Amiodarone resulting in a loss in efficacy.Approved, Investigational
TegafurThe metabolism of Tegafur can be decreased when combined with Amiodarone.Approved, Investigational
Tegafur-uracilThe metabolism of Tegafur-uracil can be decreased when combined with Amiodarone.Approved, Investigational
TegaserodThe metabolism of Tegaserod can be decreased when combined with Amiodarone.Approved, Investigational, Withdrawn
TelaprevirThe risk or severity of adverse effects can be increased when Telaprevir is combined with Amiodarone.Approved, Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Amiodarone.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Amiodarone.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Amiodarone is combined with Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Amiodarone.Approved, Investigational
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Amiodarone.Approved
TenidapTenidap may decrease the antihypertensive activities of Amiodarone.Experimental
TeniposideThe metabolism of Teniposide can be decreased when combined with Amiodarone.Approved
Tenofovir disoproxilThe metabolism of Amiodarone can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Amiodarone.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Amiodarone.Vet Approved
TerazosinAmiodarone may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
TerbutalineThe therapeutic efficacy of Terbutaline can be increased when used in combination with Amiodarone.Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Amiodarone.Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Amiodarone.Approved, Withdrawn
TeriflunomideThe serum concentration of Amiodarone can be decreased when it is combined with Teriflunomide.Approved
TertatololThe therapeutic efficacy of Tertatolol can be increased when used in combination with Amiodarone.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Amiodarone.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Amiodarone.Approved, Investigational
Testosterone cypionateThe metabolism of Testosterone cypionate can be decreased when combined with Amiodarone.Approved
Testosterone enanthateThe metabolism of Testosterone enanthate can be decreased when combined with Amiodarone.Approved
Testosterone propionateThe metabolism of Testosterone propionate can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe metabolism of Testosterone undecanoate can be decreased when combined with Amiodarone.Approved, Investigational
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Amiodarone.Approved, Investigational
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Amiodarone.Approved, Vet Approved
TezacaftorThe metabolism of Tezacaftor can be decreased when combined with Amiodarone.Approved, Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Amiodarone.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Amiodarone.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Amiodarone.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Amiodarone.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Amiodarone.Withdrawn
ThiopentalThiopental may increase the hypotensive activities of Amiodarone.Approved, Vet Approved
ThioproperazineAmiodarone may increase the orthostatic hypotensive activities of Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Amiodarone.Approved, Withdrawn
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Amiodarone.Approved, Investigational
ThiothixeneThiothixene may increase the QTc-prolonging activities of Amiodarone.Approved
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Amiodarone.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Amiodarone.Approved, Investigational
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Amiodarone.Approved
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Amiodarone resulting in a loss in efficacy.Approved
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Amiodarone.Approved
TimololThe therapeutic efficacy of Timolol can be increased when used in combination with Amiodarone.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Amiodarone.Approved, Investigational
TinoridineTinoridine may decrease the antihypertensive activities of Amiodarone.Investigational
TioclomarolThe therapeutic efficacy of Tioclomarol can be increased when used in combination with Amiodarone.Experimental
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Amiodarone.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Amiodarone.Approved
TipranavirThe serum concentration of Amiodarone can be increased when it is combined with Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Amiodarone.Approved, Withdrawn
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Amiodarone.Approved, Investigational
TocilizumabThe serum concentration of Amiodarone can be decreased when it is combined with Tocilizumab.Approved
TocofersolanThe metabolism of Tocofersolan can be decreased when combined with Amiodarone.Approved
TocopherolThe metabolism of Tocopherol can be decreased when combined with Amiodarone.Approved, Investigational
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Amiodarone.Approved, Investigational
TolazamideAmiodarone may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineAmiodarone may increase the orthostatic hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Amiodarone.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Amiodarone is combined with Tolcapone.Approved, Withdrawn
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Amiodarone.Experimental
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
TolmetinTolmetin may decrease the antihypertensive activities of Amiodarone.Approved
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Amiodarone.Approved, Investigational, Vet Approved
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Amiodarone.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Amiodarone.Approved
TopiramateThe metabolism of Amiodarone can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Amiodarone can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Amiodarone.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Amiodarone.Approved
ToremifeneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Toremifene.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Amiodarone.Approved, Investigational
TramadolThe serum concentration of Tramadol can be increased when it is combined with Amiodarone.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Trandolapril.Approved
TranilastTranilast may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
TranylcypromineThe metabolism of Amiodarone can be decreased when combined with Tranylcypromine.Approved, Investigational
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Amiodarone.Approved, Investigational
TrazodoneThe metabolism of Trazodone can be decreased when combined with Amiodarone.Approved, Investigational
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Amiodarone.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Amiodarone.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Amiodarone.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Triamterene.Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Amiodarone.Approved, Investigational
TribenosideTribenoside may decrease the antihypertensive activities of Amiodarone.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Amiodarone.Vet Approved
TrifluoperazineAmiodarone may increase the orthostatic hypotensive activities of Trifluoperazine.Approved, Investigational
TriflupromazineTriflupromazine may increase the hypotensive activities of Amiodarone.Approved, Vet Approved
TrimazosinAmiodarone may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Amiodarone.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Amiodarone.Approved, Vet Approved
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Amiodarone.Approved, Investigational
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Amiodarone.Approved
TriptolideTriptolide may decrease the antihypertensive activities of Amiodarone.Investigational
TriptorelinTriptorelin may increase the QTc-prolonging activities of Amiodarone.Approved, Vet Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Amiodarone.Investigational, Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Amiodarone.Approved
TubocurarineTubocurarine may increase the bradycardic activities of Amiodarone.Approved
TyrothricinTyrothricin may increase the bradycardic activities of Amiodarone.Approved
UdenafilThe metabolism of Udenafil can be decreased when combined with Amiodarone.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Amiodarone.Approved
UlobetasolThe serum concentration of Ulobetasol can be increased when it is combined with Amiodarone.Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Amiodarone.Approved
UrapidilAmiodarone may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Amiodarone.Approved, Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Amiodarone.Approved, Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Amiodarone.Approved, Investigational
ValsartanThe metabolism of Valsartan can be decreased when combined with Amiodarone.Approved, Investigational
VandetanibThe risk or severity of QTc prolongation can be increased when Amiodarone is combined with Vandetanib.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Amiodarone.Investigational
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Amiodarone.Approved
VareniclineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Varenicline.Approved, Investigational
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Amiodarone.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Amiodarone.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Amiodarone.Approved, Investigational
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Amiodarone.Approved
VerapamilThe risk or severity of bradycardia can be increased when Verapamil is combined with Amiodarone.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Amiodarone.Approved, Investigational
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Amiodarone.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Amiodarone.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Amiodarone.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Amiodarone.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Amiodarone.Approved, Investigational
VincristineThe metabolism of Vincristine can be decreased when combined with Amiodarone.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Amiodarone.Approved, Investigational
VinflunineThe metabolism of Vinflunine can be decreased when combined with Amiodarone.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Amiodarone.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Amiodarone.Approved, Investigational
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Amiodarone.Approved
VoriconazoleThe metabolism of Amiodarone can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Amiodarone.Approved, Investigational
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Amiodarone.Approved, Investigational
WarfarinThe therapeutic efficacy of Warfarin can be increased when used in combination with Amiodarone.Approved
WortmanninThe therapeutic efficacy of Wortmannin can be increased when used in combination with Amiodarone.Experimental
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Amiodarone.Approved, Investigational, Withdrawn
XylazineXylazine may increase the atrioventricular blocking (AV block) activities of Amiodarone.Vet Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Amiodarone.Approved, Investigational
YohimbineThe metabolism of Yohimbine can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Amiodarone.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Amiodarone.Approved, Investigational
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Amiodarone.Approved, Illicit, Investigational
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Amiodarone.Approved, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Amiodarone.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Amiodarone.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Amiodarone can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Amiodarone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Amiodarone.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Amiodarone.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Amiodarone.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Amiodarone.Approved
ZotepineThe metabolism of Zotepine can be decreased when combined with Amiodarone.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Amiodarone can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Amiodarone.Approved, Investigational
Food Interactions
  • Grapefruit and grapefruit juice should be avoided throughout treatment.
  • Grapefruit can significantly increase serum levels of this product.
  • Take without regard to meals.

References

Synthesis Reference
US3248401
General References
  1. DELTOUR G, BINON F, TONDEUR R, GOLDENBERG C, HENAUX F, SION R, DERAY E, CHARLIER R: [Studies in the benzofuran series. VI. Coronary-dilating activity of alkylated and aminoalkylated derivatives of 3-benzoylbenzofuran]. Arch Int Pharmacodyn Ther. 1962 Sep 1;139:247-54. [PubMed:14026835]
  2. CHARLIER R, DELTOUR G, TONDEUR R, BINON F: [Studies in the benzofuran series. VII. Preliminary pharmacological study of 2-butyl-3-(3,5-diiodo-4-beta-N-diethylaminoethoxybenzoyl)-benzofuran]. Arch Int Pharmacodyn Ther. 1962 Sep 1;139:255-64. [PubMed:14020244]
  3. Singh BN, Vaughan Williams EM: The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol. 1970 Aug;39(4):657-67. [PubMed:5485142]
  4. Rosenbaum MB, Chiale PA, Halpern MS, Nau GJ, Przybylski J, Levi RJ, Lazzari JO, Elizari MV: Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol. 1976 Dec;38(7):934-44. [PubMed:793369]
  5. Rosenbaum MB, Chiale PA, Haedo A, Lazzari JO, Elizari MV: Ten years of experience with amiodarone. Am Heart J. 1983 Oct;106(4 Pt 2):957-64. [PubMed:6613843]
External Links
Human Metabolome Database
HMDB0015250
KEGG Drug
D02910
KEGG Compound
C06823
PubChem Compound
2157
PubChem Substance
46507387
ChemSpider
2072
BindingDB
18957
ChEBI
2663
ChEMBL
CHEMBL633
Therapeutic Targets Database
DAP000496
PharmGKB
PA448383
IUPHAR
2566
Guide to Pharmacology
GtP Drug Page
HET
BBI
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Amiodarone
ATC Codes
C01BD01 — Amiodarone
AHFS Codes
  • 24:04.04.20 — Class III Antiarrythmics
PDB Entries
4o8z / 5h4d
FDA label
Download (545 KB)
MSDS
Download (51.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Unknown StatusPreventionPatients With Coronary Artery Disease Scheduled for by Pass Surgery1
1CompletedTreatmentHealthy Volunteers2
2CompletedPreventionProphylaxis of perioperative arrhythmia / Ventricular Arrythmias1
2CompletedTreatmentCardiac Arrest1
2WithdrawnTreatmentBlood Pressures1
3CompletedPreventionArrythmias / Cardiovascular Disease (CVD) / Heart Arrest / Heart Diseases / Myocardial Infarction / Severe ventricular arrhythmias1
3CompletedPreventionAtrial Flutter / Nonvalvular Atrial Fibrillation1
3CompletedPreventionNonvalvular Atrial Fibrillation2
3CompletedTreatmentArrythmias / Cardiovascular Disease (CVD) / Congestive Heart Failure (CHF) / Death, Sudden,Cardiac / Heart Diseases / Heart Failure, Unspecified1
3CompletedTreatmentArrythmias / Cardiovascular Disease (CVD) / Heart Diseases / Nonvalvular Atrial Fibrillation1
3CompletedTreatmentCardiac Arrest1
3CompletedTreatmentCerebrovascular Accidents / Nonvalvular Atrial Fibrillation / Sudden Death1
3CompletedTreatmentNonvalvular Atrial Fibrillation3
3CompletedTreatmentPostoperative Atrial Fibrillation1
3Not Yet RecruitingPreventionNonvalvular Atrial Fibrillation1
3RecruitingTreatmentAtrial Fibrillation in High Risk Patients / Thoracic Surgery1
3RecruitingTreatmentChagas Cardiomyopathy1
3RecruitingTreatmentHeart Diseases / Prophylaxis of cardiomyopathy / Ventricular Premature Complexes1
3SuspendedTreatmentNonvalvular Atrial Fibrillation1
3TerminatedTreatmentDefibrillators, Implantable / Ventricular Tachycardia (VT)1
3TerminatedTreatmentHeart Failure, Unspecified / Nonvalvular Atrial Fibrillation1
3Unknown StatusPreventionLung Cancers / Nonvalvular Atrial Fibrillation1
3Unknown StatusTreatmentNonvalvular Atrial Fibrillation1
4Active Not RecruitingTreatmentHeart Failure, Unspecified1
4CompletedPreventionCoronary Artery Bypass Grafting (CABG) Surgery / Nonvalvular Atrial Fibrillation1
4CompletedPreventionNonvalvular Atrial Fibrillation1
4CompletedPreventionNonvalvular Atrial Fibrillation / Oesophagectomy1
4CompletedPreventionNonvalvular Atrial Fibrillation / Surgery, Cardiac1
4CompletedTreatmentNonvalvular Atrial Fibrillation2
4CompletedTreatmentRecurrent Ventricular Tachycardia1
4Enrolling by InvitationTreatmentNew Onset Atrial Fibrillation / Severe Sepsis / Shock, Septic1
4Not Yet RecruitingTreatmentNonvalvular Atrial Fibrillation1
4Not Yet RecruitingTreatmentProphylaxis of cardiomyopathy / Ventricular Premature Beats, Contractions, or Systoles1
4RecruitingTreatmentArrhythmias Ventricular1
4RecruitingTreatmentHeart Failure, Unspecified / Nonvalvular Atrial Fibrillation1
4RecruitingTreatmentMyocardial Infarction / Ventricular Tachyarrhythmias1
4RecruitingTreatmentNonvalvular Atrial Fibrillation1
4Unknown StatusPreventionNonvalvular Atrial Fibrillation1
4WithdrawnTreatmentNonvalvular Atrial Fibrillation1
Not AvailableActive Not RecruitingTreatmentNonvalvular Atrial Fibrillation / Quality of Life1
Not AvailableCompletedNot AvailableAtrial Tachycardia / Nonvalvular Atrial Fibrillation1
Not AvailableCompletedNot AvailableDeath, Sudden,Cardiac / Heart Arrest1
Not AvailableCompletedPreventionNonvalvular Atrial Fibrillation1
Not AvailableCompletedPreventionOther Intraoperative Cardiac Functional Disturbances During Cardiac Surgery1
Not AvailableCompletedTreatmentArrythmias / Nonvalvular Atrial Fibrillation1
Not AvailableCompletedTreatmentNonvalvular Atrial Fibrillation2
Not AvailableCompletedTreatmentPersistant Atrial Fibrillation1
Not AvailableNot Yet RecruitingTreatmentAt Least 10 Points in Rassi Risk Score for Death / Chagas Cardiomyopathy / Non-sustained Ventricular Tachycardia1
Not AvailableRecruitingPreventionNonvalvular Atrial Fibrillation1
Not AvailableRecruitingTreatmentHeart Failure, Unspecified / Recurrent Atrial Fibrillation1
Not AvailableRecruitingTreatmentNonvalvular Atrial Fibrillation1
Not AvailableTerminatedTreatmentMitral Valvulopathy / Nonvalvular Atrial Fibrillation1
Not AvailableTerminatedTreatmentNonvalvular Atrial Fibrillation1
Not AvailableTerminatedTreatmentVentricular Tachycardia (VT)2
Not AvailableUnknown StatusTreatmentNonvalvular Atrial Fibrillation1
Not AvailableUnknown StatusTreatmentSurgery, Cardiac1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Alphapharm Party Ltd.
  • Amerisource Health Services Corp.
  • Amphastar Pharmaceuticals
  • Apotex Inc.
  • APP Pharmaceuticals
  • A-S Medication Solutions LLC
  • Aurolife Pharma LLC
  • Aurosal Pharmaceuticals LLC
  • Barr Pharmaceuticals
  • Baxter International Inc.
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • Bioniche Pharma
  • Cadila Healthcare Ltd.
  • Cardinal Health
  • Caremark LLC
  • Diversified Healthcare Services Inc.
  • Eon Labs
  • General Injectables and Vaccines Inc.
  • Gland Pharma Ltd.
  • Heartland Repack Services LLC
  • Hikma Pharmaceuticals
  • Hospira Inc.
  • Mckesson Corp.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Murty Pharmaceuticals Inc.
  • Mylan
  • Neuman Distributors Inc.
  • Novex Pharma
  • Novopharm Ltd.
  • Par Pharmaceuticals
  • Physicians Total Care Inc.
  • Prepak Systems Inc.
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Sagent Pharmaceuticals
  • Sandhills Packaging Inc.
  • Sandoz
  • Sanofi-Aventis Inc.
  • Sicor Pharmaceuticals
  • Spectrum Pharmaceuticals
  • Taro Pharmaceuticals USA
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Upsher Smith Laboratories
  • Vangard Labs Inc.
  • West-Ward Pharmaceuticals
  • Wockhardt Ltd.
  • Wyeth Pharmaceuticals
  • Zydus Pharmaceuticals
Dosage forms
FormRouteStrength
Injection, solutionIntravenous1.8 mg/mL
InjectionIntravenous50 mg/mL
Injection, solutionIntravenous150 mg/3mL
Injection, solutionIntravenous450 mg/9mL
Injection, solutionIntravenous50 mg/mL
Injection, solutionIntravenous900 mg/18mL
Injection, solution, concentrateIntravenous50 mg/mL
TabletOral100 mg/1
TabletOral200 mg/1
TabletOral300 mg/1
TabletOral400 mg/1
LiquidIntravenous50 mg
SolutionIntravenous50 mg
Injection, solutionIntravenous1.5 mg/mL
TabletOral100 mg
TabletOral200 mg
Prices
Unit descriptionCostUnit
Amiodarone hcl powder38.98USD g
Pacerone 100 mg tablet7.58USD tablet
Pacerone 400 mg tablet7.43USD tablet
Amiodarone hcl 400 mg tablet6.32USD tablet
Cordarone 200 mg tablet4.78USD tablet
Pacerone 200 mg tablet3.53USD tablet
Amiodarone hcl 200 mg tablet3.37USD tablet
Cordarone 200 mg Tablet2.32USD tablet
Apo-Amiodarone 200 mg Tablet1.3USD tablet
Mylan-Amiodarone 200 mg Tablet1.3USD tablet
Novo-Amiodarone 200 mg Tablet1.3USD tablet
Pms-Amiodarone 200 mg Tablet1.3USD tablet
Ratio-Amiodarone 200 mg Tablet1.3USD tablet
Sandoz Amiodarone 200 mg Tablet1.3USD tablet
Amiodarone 150 mg/3 ml vial0.83USD ml
Pms-Amiodarone 100 mg Tablet0.72USD tablet
Amiodarone 900 mg/18 ml vial0.59USD ml
Amiodarone 450 mg/9 ml vial0.57USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5134127No1993-01-232010-01-23Us
US6869939No2002-05-042022-05-04Us
US7635773No2009-03-132029-03-13Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)156Tondeur, R. and Binon, F.; U.S. Patent 3,248,401; April 26,1966; assigned to Societe Beige de I'Azote et des Produits Chimiques du Marly, SA, Belgium.
water solubilityLowNot Available
logP7.57AVDEEF,A (1997)
Predicted Properties
PropertyValueSource
Water Solubility0.00476 mg/mLALOGPS
logP7.24ALOGPS
logP7.64ChemAxon
logS-5.1ALOGPS
pKa (Strongest Basic)8.47ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area42.68 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity145.05 m3·mol-1ChemAxon
Polarizability56.78 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8615
Caco-2 permeable+0.66
P-glycoprotein substrateSubstrate0.8044
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterInhibitor0.5099
CYP450 2C9 substrateNon-substrate0.7959
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7188
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8615
Ames testNon AMES toxic0.5661
CarcinogenicityNon-carcinogens0.7696
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6539 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5932
hERG inhibition (predictor II)Inhibitor0.7638
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0000009000-8cbab89986761a7a1bc9
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0pbj-9300003000-503a542bf1a7678f385e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9110000000-543b8de3c9ba390fa765
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0791000000-77d5d18989052c45b006
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a59-0980000000-a77e32d189cf8e2acdf1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0apl-0940000000-30e016c113387b37ca7c
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-0000009000-e87a9a6e983c00161beb

Taxonomy

Description
This compound belongs to the class of organic compounds known as aryl-phenylketones. These are aromatic compounds containing a ketone substituted by one aryl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Aryl-phenylketones
Alternative Parents
Benzofurans / Phenoxy compounds / Phenol ethers / Benzoyl derivatives / 3-aroylfurans / Iodobenzenes / Alkyl aryl ethers / Aryl iodides / Heteroaromatic compounds / Trialkylamines
show 5 more
Substituents
Aryl-phenylketone / Benzofuran / Phenol ether / 3-aroylfuran / Benzoyl / Phenoxy compound / Alkyl aryl ether / Halobenzene / Iodobenzene / Benzenoid
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tertiary amino compound, organoiodine compound, 1-benzofurans, aromatic ketone (CHEBI:2663)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Wang SP, Wang JA, Luo RH, Cui WY, Wang H: Potassium channel currents in rat mesenchymal stem cells and their possible roles in cell proliferation. Clin Exp Pharmacol Physiol. 2008 Sep;35(9):1077-84. doi: 10.1111/j.1440-1681.2008.04964.x. Epub 2008 May 25. [PubMed:18505444]
  3. Varro A, Biliczki P, Iost N, Virag L, Hala O, Kovacs P, Matyus P, Papp JG: Theoretical possibilities for the development of novel antiarrhythmic drugs. Curr Med Chem. 2004 Jan;11(1):1-11. [PubMed:14754422]
  4. Waldhauser KM, Brecht K, Hebeisen S, Ha HR, Konrad D, Bur D, Krahenbuhl S: Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues. Br J Pharmacol. 2008 Oct;155(4):585-95. doi: 10.1038/bjp.2008.287. Epub 2008 Jul 7. [PubMed:18604229]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Doggrell SA, Brown L: Present and future pharmacotherapy for heart failure. Expert Opin Pharmacother. 2002 Jul;3(7):915-30. [PubMed:12083991]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1H
Uniprot ID
O95180
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1H
Molecular Weight
259160.2 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221]
  2. Lewalter T, Pittrow D, Goette A, Kirch W, Hohnloser S: [Clinical pharmacology and electrophysiological properties of dronedarone]. Dtsch Med Wochenschr. 2010 Mar;135 Suppl 2:S43-7. doi: 10.1055/s-0030-1249208. Epub 2010 Mar 10. [PubMed:20221978]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-t...
Gene Name
CACNA2D2
Uniprot ID
Q9NY47
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-2
Molecular Weight
129816.095 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221]
  2. Lewalter T, Pittrow D, Goette A, Kirch W, Hohnloser S: [Clinical pharmacology and electrophysiological properties of dronedarone]. Dtsch Med Wochenschr. 2010 Mar;135 Suppl 2:S43-7. doi: 10.1055/s-0030-1249208. Epub 2010 Mar 10. [PubMed:20221978]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Isoform Alpha-1: Nuclear hormone receptor that can act as a repressor or activator of transcription. High affinity receptor for thyroid hormones, including triiodothyronine and thyroxine.Isoform Al...
Gene Name
THRA
Uniprot ID
P10827
Uniprot Name
Thyroid hormone receptor alpha
Molecular Weight
54815.055 Da
References
  1. Carlsson B, Singh BN, Temciuc M, Nilsson S, Li YL, Mellin C, Malm J: Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone. J Med Chem. 2002 Jan 31;45(3):623-30. [PubMed:11806713]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor that can act as a repressor or activator of transcription. High affinity receptor for thyroid hormones, including triiodothyronine and thyroxine.
Gene Name
THRB
Uniprot ID
P10828
Uniprot Name
Thyroid hormone receptor beta
Molecular Weight
52787.16 Da
References
  1. Carlsson B, Singh BN, Temciuc M, Nilsson S, Li YL, Mellin C, Malm J: Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone. J Med Chem. 2002 Jan 31;45(3):623-30. [PubMed:11806713]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE...
Gene Name
PPARG
Uniprot ID
P37231
Uniprot Name
Peroxisome proliferator-activated receptor gamma
Molecular Weight
57619.58 Da
References
  1. Szalowska E, van der Burg B, Man HY, Hendriksen PJ, Peijnenburg AA: Model steatogenic compounds (amiodarone, valproic acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices. PLoS One. 2014 Jan 29;9(1):e86795. doi: 10.1371/journal.pone.0086795. eCollection 2014. [PubMed:24489787]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Elsherbiny ME, El-Kadi AO, Brocks DR: The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci. 2008;11(1):147-59. [PubMed:18445370]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, Yokoi T: A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos. 2000 Nov;28(11):1303-10. [PubMed:11038157]
  5. Clin-Info. (2006). In Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals (pp. L53). Canadian Pharmacists Association. [ISBN:1-894402-22-7]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  7. Electronic Medicines Compendium Amiodarone 100mg Tablets [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, Yokoi T: A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos. 2000 Nov;28(11):1303-10. [PubMed:11038157]
  4. Clin-Info. (2006). In Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals (pp. L53). Canadian Pharmacists Association. [ISBN:1-894402-22-7]
  5. Website [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Yamreudeewong W, DeBisschop M, Martin LG, Lower DL: Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf. 2003;26(6):421-38. [PubMed:12688833]
  4. Clin-Info. (2006). In Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals (pp. L53). Canadian Pharmacists Association. [ISBN:1-894402-22-7]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Yamreudeewong W, DeBisschop M, Martin LG, Lower DL: Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf. 2003;26(6):421-38. [PubMed:12688833]
  3. Naganuma M, Shiga T, Nishikata K, Tsuchiya T, Kasanuki H, Fujii E: Role of desethylamiodarone in the anticoagulant effect of concurrent amiodarone and warfarin therapy. J Cardiovasc Pharmacol Ther. 2001 Oct;6(4):363-7. doi: 10.1177/107424840100600405. [PubMed:11907638]
  4. Heimark LD, Wienkers L, Kunze K, Gibaldi M, Eddy AC, Trager WF, O'Reilly RA, Goulart DA: The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther. 1992 Apr;51(4):398-407. [PubMed:1563209]
  5. Clin-Info. (2006). In Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals (pp. L53). Canadian Pharmacists Association. [ISBN:1-894402-22-7]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  7. Drug Interactions & Labeling - FDA [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Elsherbiny ME, El-Kadi AO, Brocks DR: The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci. 2008;11(1):147-59. [PubMed:18445370]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T: Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol. 2000 Mar;49(3):244-53. [PubMed:10718780]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8. [PubMed:8632764]
  2. Katoh M, Nakajima M, Yamazaki H, Yokoi T: Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci. 2001 Feb;12(4):505-13. [PubMed:11231118]
  3. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267]
  4. Tiberghien F, Loor F: Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs. 1996 Jul;7(5):568-78. [PubMed:8862725]
  5. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14. [PubMed:10213372]

Drug created on June 13, 2005 07:24 / Updated on June 23, 2018 21:19